PL1737428T3 - Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych - Google Patents

Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych

Info

Publication number
PL1737428T3
PL1737428T3 PL05732710T PL05732710T PL1737428T3 PL 1737428 T3 PL1737428 T3 PL 1737428T3 PL 05732710 T PL05732710 T PL 05732710T PL 05732710 T PL05732710 T PL 05732710T PL 1737428 T3 PL1737428 T3 PL 1737428T3
Authority
PL
Poland
Prior art keywords
arthritis
evaluation
treatment
delivery systems
inflammatory diseases
Prior art date
Application number
PL05732710T
Other languages
English (en)
Inventor
Dong Wang
Jindrich Kopecek
Scott C. Miller
Pavla Kopecková
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Publication of PL1737428T3 publication Critical patent/PL1737428T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • A61K49/126Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05732710T 2004-03-31 2005-03-30 Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych PL1737428T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55804704P 2004-03-31 2004-03-31
PCT/US2005/010801 WO2005097073A1 (en) 2004-03-31 2005-03-30 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
EP05732710.8A EP1737428B1 (en) 2004-03-31 2005-03-30 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases

Publications (1)

Publication Number Publication Date
PL1737428T3 true PL1737428T3 (pl) 2018-03-30

Family

ID=35124812

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05732710T PL1737428T3 (pl) 2004-03-31 2005-03-30 Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych

Country Status (9)

Country Link
US (2) US10092662B2 (pl)
EP (2) EP1737428B1 (pl)
CA (1) CA2557448C (pl)
DK (1) DK1737428T3 (pl)
ES (1) ES2641570T3 (pl)
HU (1) HUE034923T2 (pl)
PL (1) PL1737428T3 (pl)
PT (1) PT1737428T (pl)
WO (1) WO2005097073A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1737428T3 (en) 2004-03-31 2017-10-09 Univ Utah Res Found MACROMOLECULAR ADMINISTRATION SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES
EP1647283A1 (en) * 2004-10-12 2006-04-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Polymeric contrast agent
EP1902734A1 (en) * 2006-09-25 2008-03-26 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts uPAR selective contrast agent for magnetic resonance imaging
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
DE102007041625A1 (de) * 2007-09-03 2009-03-05 Sinn, Hannsjörg, Dr. Neue Gelatine-Wirkstoff-Konjugate
EP3338816A1 (en) * 2009-09-09 2018-06-27 Board Of Regents Of The University Of Nebraska Compositions and methods for detecting and treating implant loosening and osteolysis
US20110158901A1 (en) * 2009-12-29 2011-06-30 Swadeshmukul Santra Chitosan-based nanoparticles and methods for making and using the same
CN102811707A (zh) 2010-02-08 2012-12-05 内布拉斯加大学董事委员会 结合生物矿物和金属的脂质体,它们的合成以及其使用方法
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
WO2012061695A1 (en) 2010-11-04 2012-05-10 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of traumatic brain injury
WO2014008469A2 (en) 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Methods of treating arthritis
CA3004444C (en) 2015-11-12 2024-01-02 Board Of Regents Of The University Of Nebraska Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
WO2017090047A1 (en) 2015-11-27 2017-06-01 Technology Innovation Momentum Fund (Israel) Limited Partnership Glucosamine and derivatives thereof in imaging
CN105797174B (zh) * 2016-01-22 2019-01-11 复旦大学附属肿瘤医院 一种基于纳米氧化石墨烯的磁共振成像造影剂及其制备方法
US20210393811A1 (en) * 2018-10-05 2021-12-23 Texas Heart Institute Imaging Agents and Methods of Use
CN113415908B (zh) * 2021-05-19 2022-04-29 河北津宏化工有限公司 一种改性水解聚马来酸酐水处理剂及其制备方法
CN116076438B (zh) * 2023-03-21 2024-01-30 湖南中医药大学 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034040A (en) 1971-05-24 1977-07-05 Pfizer Inc. Xylene-diamines as antiviral agents
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
DK110188D0 (da) * 1988-03-02 1988-03-02 Claus Selch Larsen High molecular weight prodrug derivatives of antiinflammatory drugs
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US6528057B1 (en) 1998-08-31 2003-03-04 Julian L. Ambrus Method for removal of HIV and other viruses from blood
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US20040043030A1 (en) * 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
KR20050059001A (ko) * 2002-07-01 2005-06-17 사비언트 파마슈티컬즈 인코퍼레이티드 치료적 처리를 위한 조성물 및 방법
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
DK1737428T3 (en) 2004-03-31 2017-10-09 Univ Utah Res Found MACROMOLECULAR ADMINISTRATION SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES

Also Published As

Publication number Publication date
US20180207296A1 (en) 2018-07-26
EP1737428A1 (en) 2007-01-03
WO2005097073A1 (en) 2005-10-20
EP1737428A4 (en) 2010-12-22
HUE034923T2 (en) 2018-03-28
DK1737428T3 (en) 2017-10-09
EP3269394A1 (en) 2018-01-17
PT1737428T (pt) 2017-10-02
US20080159959A1 (en) 2008-07-03
ES2641570T3 (es) 2017-11-10
US10172962B2 (en) 2019-01-08
CA2557448C (en) 2015-06-23
CA2557448A1 (en) 2005-10-20
EP1737428B1 (en) 2017-08-30
US10092662B2 (en) 2018-10-09
WO2005097073A8 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
PL1737428T3 (pl) Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
WO2007147019A3 (en) Il-17 and il-23 antagonists and methods of using the same
EP1824410A4 (en) SYSTEMS AND METHODS FOR INTRAORAL DRUG DELIVERY
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2712930A3 (en) Interferon alpha-induced pharmacodynamic markers
EP1846080A4 (en) SYSTEM AND METHOD FOR DISTRIBUTING THERAPEUTIC AGENT
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式,其組合物,及其用途
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
IL178815A0 (en) The treatment of respiratory disease
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP2021016A4 (en) CXCL13 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
IL178827A0 (en) Use of reboxetine for the treatment of pain
IL204584A0 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
EP1724271A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENT AGAINST NEUTROPHIC INFLAMMATORY DISEASE
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
EP1843781A4 (en) COMPOSITION FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF INFLAMMATORY CHRONIC DISEASES OF AIRWAYS